Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Abevmy (Bevacizumab) is a biosimilar medication widely used in the treatment of various types of cancer, including colorectal, lung, glioblastoma, kidney, and ovarian cancers. As a monoclonal antibody, Abevmy works by targeting and inhibiting vascular endothelial growth factor (VEGF), a protein responsible for stimulating the growth of blood vessels. By blocking this protein, Abevmy effectively starves the tumor cells by preventing the formation of new blood vessels, thereby inhibiting tumor growth.
This medication is a part of targeted therapy, offering a focused approach to cancer treatment by interfering with specific molecules involved in tumor growth and progression. Its precision and mode of action make it a cornerstone in the management of several advanced cancers, particularly for patients who are not candidates for surgery. Before you buy Abevmy, it is crucial that you talk to your healthcare provider about potential side effects and bevacizumab price.
| Fact Table | |
|---|---|
| Formula | C6638H10160N1720O2108S44 |
| License | FDA approved |
| Bioavailability | Not applicable (IV administration) |
| Legal status | Prescription only |
| Chemical Name | Bevacizumab |
| Elimination half-life | 20 days |
| Dosage (Strength) | 100 mg and 400 mg per vial |
| Pregnancy | Contraindicated; may cause fetal harm |
| Brands | Abevmy, Avastin |
| Protein binding | Not applicable |
| PubChem CID | 24872366 |
| MedlinePlus | a607002 |
| ChEBI | CHEBI:506227 |
| ATC code | L01XC07 |
| DrugBank | DB00112 |
| KEGG | D03259 |
| Routes of administration | Intravenous |
Abevmy (Bevacizumab) should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents. It is typically given as an infusion into a vein (intravenous, IV) over 90 minutes for the first dose. If the first infusion is tolerated well, subsequent doses may be given over 60 to 30 minutes.
The dosage and treatment schedule depend on the type of cancer being treated, the general health of the patient, and how well the patient tolerates the treatment. Regular monitoring through follow-up appointments is crucial to adjust the therapy as needed and manage any side effects.
The active ingredient in Abevmy is bevacizumab.
Before starting bevacizumab injection, patients should discuss their full medical history with their healthcare provider. Abevmy is contraindicated in patients with hypersensitivity to bevacizumab or any of its components and in women who are pregnant or breastfeeding due to potential harm to the fetus or baby.
Patients should be closely monitored for signs of severe side effects, including gastrointestinal perforations, wound healing complications, hemorrhage, and thromboembolic events. Due to its mechanism of action, Abevmy can also increase the risk of arterial thromboembolic events such as angina or myocardial infarction.
Abevmy can interact with other medications, which can either reduce its effectiveness or increase side effects. It is important to inform the healthcare provider of all medications being taken, including over-the-counter drugs, herbal supplements, and vitamins. Special caution should be used when combining Abevmy with anticoagulants or any medication known to affect wound healing.
The use of Abevmy can lead to various side effects, which can range from mild to severe. Common side effects include:
What is bevacizumab?
Bevacizumab is a monoclonal antibody that is used as an anti-cancer medication. It works by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that promotes the growth of new blood vessels (angiogenesis). This inhibition helps to starve tumors of their blood supply, thereby slowing or stopping their growth.
Is bevacizumab immunotherapy?
No, bevacizumab is not considered immunotherapy. It is a type of targeted therapy known as an angiogenesis inhibitor. While immunotherapy works by stimulating the body's immune system to attack cancer cells, bevacizumab specifically targets and inhibits the VEGF-A protein to prevent blood vessel growth in tumors.
Does bevacizumab cause hair loss?
Hair loss is not a common side effect of bevacizumab. The most frequent side effects include high blood pressure, fatigue, blood clots, bleeding, and gastrointestinal perforations. However, patients undergoing combination treatments that include chemotherapy might experience hair loss due to the chemotherapy drugs.
How does bevacizumab work?
Bevacizumab works by binding to VEGF-A, a protein that stimulates the formation of blood vessels. By inhibiting this protein, bevacizumab prevents the growth of new blood vessels that supply oxygen and nutrients to tumors, thereby inhibiting tumor growth and spread.
How is bevacizumab administered?
Bevacizumab is administered as an intravenous (IV) infusion. The dosage and frequency of administration depend on the type of cancer being treated and other individual patient factors. Infusions are typically given every two to three weeks.
Is bevacizumab FDA approved?
Yes, bevacizumab is FDA approved. It has been approved for the treatment of several types of cancer, including colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer, among others.
What is the success rate of bevacizumab?
The success rate of bevacizumab varies depending on the type of cancer and the individual patient's response to the treatment. Clinical trials and studies have shown that bevacizumab can significantly improve progression-free survival in certain cancers. However, overall survival benefits can vary and should be discussed with a healthcare provider for specific cancer types.
What is the life expectancy after bevacizumab?
Life expectancy after bevacizumab treatment depends on many factors, including the type and stage of cancer, overall health of the patient, and how well the cancer responds to treatment. Bevacizumab can help to extend life expectancy in some patients by slowing the progression of the disease, but it is not a cure. Detailed prognosis should be discussed with a healthcare provider.
What cancers does bevacizumab treat?
Bevacizumab is used to treat various cancers, including:
How long is a bevacizumab injection?
The initial bevacizumab infusion usually takes about 90 minutes. If well tolerated, subsequent infusions may take about 30 to 60 minutes. The exact duration can vary based on the specific protocol and patient response.
